Autonomix Medical Adds Medtronic Regulatory Veteran to Board
Event summary
- Autonomix Medical appointed Sandra Cohen Kalter, former Medtronic Chief Regulatory Counsel, to its Board of Directors on September 16, 2026.
- Kalter brings over 40 years of MedTech experience, including 20 years at Medtronic where she oversaw 27 acquisitions and key regulatory strategies.
- Her expertise spans renal denervation, electrophysiology, and other category-defining technologies.
- Kalter will provide strategic guidance as Autonomix advances its nerve-targeted treatment technologies and evaluates industry partnerships.
The big picture
Autonomix Medical is bolstering its governance with deep MedTech regulatory and transactional expertise at a critical stage of its development. The appointment of Sandra Cohen Kalter, who played a pivotal role in Medtronic’s strategic growth and regulatory navigation, underscores Autonomix’s push toward clinical validation and broader industry partnerships. Her experience with category-defining technologies positions Autonomix to navigate complex regulatory pathways and evaluate strategic opportunities more effectively.
What we're watching
- Regulatory Navigation
- How Kalter’s FDA and regulatory experience will shape Autonomix’s path to clinical development and approval.
- Strategic Partnerships
- Whether Kalter’s acquisition and integration expertise can accelerate Autonomix’s industry collaborations.
- Technology Expansion
- The pace at which Autonomix can leverage Kalter’s insights to expand its platform across additional therapeutic applications.